TOT BIOPHARM International Company Limited

SEHK:1875 株式レポート

時価総額:HK$1.7b

このページの翻訳は実験的なもので、現在開発中です。お待ちしております!

TOT BIOPHARM International マネジメント

マネジメント 基準チェック /24

現在、CEO に関する十分な情報がありません。

主要情報

Jun Liu

最高経営責任者

CN¥7.5m

報酬総額

CEO給与比率49.5%
CEO在任期間5.3yrs
CEOの所有権n/a
経営陣の平均在職期間3.8yrs
取締役会の平均在任期間5.3yrs

経営陣の近況

We Think Some Shareholders May Hesitate To Increase TOT BIOPHARM International Company Limited's (HKG:1875) CEO Compensation

Jun 07
We Think Some Shareholders May Hesitate To Increase TOT BIOPHARM International Company Limited's (HKG:1875) CEO Compensation

Recent updates

We Think Some Shareholders May Hesitate To Increase TOT BIOPHARM International Company Limited's (HKG:1875) CEO Compensation

Jun 07
We Think Some Shareholders May Hesitate To Increase TOT BIOPHARM International Company Limited's (HKG:1875) CEO Compensation

The Market Lifts TOT BIOPHARM International Company Limited (HKG:1875) Shares 29% But It Can Do More

May 21
The Market Lifts TOT BIOPHARM International Company Limited (HKG:1875) Shares 29% But It Can Do More

Is TOT BIOPHARM International (HKG:1875) Using Debt In A Risky Way?

Mar 18
Is TOT BIOPHARM International (HKG:1875) Using Debt In A Risky Way?

There's No Escaping TOT BIOPHARM International Company Limited's (HKG:1875) Muted Revenues

Dec 28
There's No Escaping TOT BIOPHARM International Company Limited's (HKG:1875) Muted Revenues

Does TOT BIOPHARM International (HKG:1875) Have A Healthy Balance Sheet?

Nov 23
Does TOT BIOPHARM International (HKG:1875) Have A Healthy Balance Sheet?

We Think TOT BIOPHARM International (HKG:1875) Has A Fair Chunk Of Debt

May 18
We Think TOT BIOPHARM International (HKG:1875) Has A Fair Chunk Of Debt

Here's Why We're Watching TOT BIOPHARM International's (HKG:1875) Cash Burn Situation

Jul 27
Here's Why We're Watching TOT BIOPHARM International's (HKG:1875) Cash Burn Situation

An Intrinsic Calculation For TOT BIOPHARM International Company Limited (HKG:1875) Suggests It's 41% Undervalued

Mar 26
An Intrinsic Calculation For TOT BIOPHARM International Company Limited (HKG:1875) Suggests It's 41% Undervalued

Here's Why We're Watching TOT BIOPHARM International's (HKG:1875) Cash Burn Situation

Feb 03
Here's Why We're Watching TOT BIOPHARM International's (HKG:1875) Cash Burn Situation

CEO報酬分析

TOT BIOPHARM International の収益と比較して、Jun Liu の報酬はどのように変化したか?
日付総報酬給与会社業績
Dec 31 2023CN¥8mCN¥4m

-CN¥38m

Sep 30 2023n/an/a

-CN¥44m

Jun 30 2023n/an/a

-CN¥49m

Mar 31 2023n/an/a

-CN¥50m

Dec 31 2022CN¥5mCN¥3m

-CN¥50m

Sep 30 2022n/an/a

-CN¥106m

Jun 30 2022n/an/a

-CN¥162m

Mar 31 2022n/an/a

-CN¥212m

Dec 31 2021CN¥3mCN¥2m

-CN¥261m

報酬と市場: Junの 総報酬 ($USD 1.04M ) は、 Hong Kong市場 ($USD 351.57K ) の同規模の企業の平均を上回っています。

報酬と収益: Junの報酬は増加しましたが、会社は利益を上げていません。


CEO(最高経営責任者

Jun Liu (56 yo)

5.3yrs

在職期間

CN¥7,528,000

報酬

Dr. Jun Liu serves as Chief Executive Officer at TOT BIOPHARM International Company Limited since October 15, 2020 and serves as its Executive Director since October 26, 2018. Dr. Liu serves as Chief Scien...


リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Jun Liu
CEO, Chief Scientific Officer & Executive Director5.3yrsCN¥7.53mデータなし
Ben Xiao
Executive Finance Director2.4yrsデータなしデータなし
Wing Yat Lui
Joint Company Secretary5.3yrsデータなしデータなし
Yifan Chen
Joint Company Secretary2.4yrsデータなしデータなし

3.8yrs

平均在職期間

43yo

平均年齢

経験豊富な経営陣: 1875の経営陣は 経験豊富 であると考えられます ( 3.8年の平均在職年数)。


取締役

名称ポジション在職期間報酬所有権
Jun Liu
CEO, Chief Scientific Officer & Executive Director5.8yrsCN¥7.53mデータなし
Shan Fu
Chairman of the Board8.5yrsデータなしデータなし
Hong-Jen Chang
Independent Non-Executive Director5.3yrsCN¥282.00kデータなし
Chun-Ying Yeh-Huang
Non-Executive Vice Chairman of the Board8.5yrsCN¥600.00k0.71%
CN¥ 12.0m
Lan Hu
Independent Non-Executive Director5.3yrsCN¥282.00kデータなし
Weidong Liu
Non-Executive Directorless than a yearデータなしデータなし
De Qian Wang
Independent Non-Executive Director2.3yrsCN¥282.00kデータなし

5.3yrs

平均在職期間

56yo

平均年齢

経験豊富なボード: 1875の 取締役会経験豊富 であると考えられます ( 5.3年の平均在任期間)。